Los puntos clave no están disponibles para este artículo en este momento.
Although the initial clinical experience is promising, significant challenges to the success of neoantigen vaccines include limitations in neoantigen identification and the need to successfully target the immunosuppressive tumor microenvironment.
Supabphol et al. (Mon,) studied this question.